NVIDIA
NVDA
Meta Platforms
META
Oracle
ORCL
MicroStrategy
MSTR
Salesforce
CRM
US Stock MarketDetailed Quotes
TCRX TScan Therapeutics
- 3.065
- +0.095+3.20%
Trading Dec 18 14:02 ET
163.58MMarket Cap-3.23P/E (TTM)
3.100High2.960Low205.05KVolume3.020Open2.970Pre Close615.68KTurnover0.64%Turnover RatioLossP/E (Static)53.37MShares9.69052wk High0.71P/B98.94MFloat Cap2.60052wk Low--Dividend TTM32.28MShs Float14.710Historical High--Div YieldTTM4.71%Amplitude1.450Historical Low3.002Avg Price1Lot Size
TScan Therapeutics Key Stats
EPS
According to the latest financial report of TScan Therapeutics, the latest earnings per share (TTM) for the company is -0.25. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about TScan Therapeutics's free cash flow? The latest report shows it as -29.29M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of TScan Therapeutics shows that the company's current ratio is 9.56, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of TScan Therapeutics, the quick ratio is 9.46, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of TScan Therapeutics? The latest ROE figure is -12.34%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of TScan Therapeutics, the total asset return on investment (ROA) is -8.27%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check TScan Therapeutics's latest financial report to see how their gross margin is doing - currently at --.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of TScan Therapeutics, the net profit margin is -2.85K%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.